



# The Open PHArmacological Concepts Triple Store

Egon Willighagen

Dept of Bioinformatics – BiGCaT, Maastricht University

@egonwillighagen, #oteu13



# The Innovative Medicines Initiative

- EC funded public-private partnership for pharmaceutical research
- Focus on key problems
  - Efficacy, Safety,
     Education & Training,
     Knowledge
     Management



#### The Open PHACTS Project

- Create a semantic integration hub ("Open Pharmacological Space")...
- Delivering services to support
- Work split into clusters:
  - Technical Build (focus here)
  - Scientific Drive
  - Community & Sustainability

# The Project



#### **Open PHACTS Project Partners**

#### Pfizer Limited - Coordinator

#### Universität Wien – Managing entity

Technical University of Denmark

University of Hamburg, Center for Bioinformatics

BioSolveIT GmBH

Consorci Mar Parc de Salut de Barcelona

Leiden University Medical Centre

Royal Society of Chemistry

Vrije Universiteit Amsterdam

Spanish National Cancer Research Centre

University of Manchester

Maastricht University

Agnowledge

University of Santiago de Compostela

Rheinische Friedrich-Wilhelms-Universität Bonn

AstraZeneca

GlaxoSmithKline

Esteve

#### www.openphacts.org

Novartis

Merck Serono

H. Lundbeck A/S

Eli Lilly

Netherlands Bioinformatics Centre

Swiss Institute of Bioinformatics

ConnectedDiscovery

**EMBL-European Bioinformatics Institute** 

Janssen

OpenLink























































# Research Questions Open PHACTS Open Pharmacological Space



Number	sum	Nr of 1	Question
15	12	9	All oxido, reductase inhibitors active <100nM in both human and mouse
18	14	8	Given compound X, what is its predicted secondary pharmacology? What are the on and off,target safety concerns for a compound? What is the evidence and how reliable is that evidence (journal impact factor, KOL) for findings associated with a compound?
24	13	8	Given a target find me all actives against that target. Find/predict polypharmacology of actives. Determine ADMET profile of actives.
32	13	8	For a given interaction profile, give me compounds similar to it.
37	13	8	The current Factor Xa lead series is characterised by substructure X. Retrieve all bioactivity data in serine protease assays for molecules that contain substructure X.
38	13	8	Retrieve all experimental and clinical data for a given list of compounds defined by their chemical structure (with options to match stereochemistry or not).
41	13	8	A project is considering Protein Kinase C Alpha (PRKCA) as a target. What are all the compounds known to modulate the target directly? What are the compounds that may modulate the target directly? i.e. return all cmpds active in assays where the resolution is at least at the level of the target family (i.e. PKC) both from structured assay databases and the literature.
44	13	8	Give me all active compounds on a given target with the relevant assay data
46	13	8	Give me the compound(s) which hit most specifically the multiple targets in a given pathway (disease)
59	14	8	Identify all known protein-protein interaction inhibitors

#### What do we need?



"What is the selectivity profile of known p38 inhibitors?"



"Let me compare MW, logP and PSA for known oxidoreductase inhibitors"



"Find me compounds that inhibit targets in NFkB pathway assayed in only functional assays with a potency <1 μM"



DrugBank

Gene Ontology

Wikipathways

GeneGo

ChEBI

**ChEMBL** 

Uniprot

**UMLS** 

**GVKBio** 

ConceptWiki

ChemSpider

TrialTrove

TR Integrity

The Open PHACTS infrastructure can support many different domains & questions

### **Quantitative Data Challenges**



STANDARD_TYPE UNIT_COUNT						
AC50	7	STANDARD_TYPE	STANDARD_UNITS	COUNT (*)		
Activity EC50	421	IC50	nM	829448		
IC50 ID50	46 42	IC50 IC50	ug.mL-1	41000 38521		
Ki	23	IC50 IC50	ug/ml ug ml-1	2038 509		
Log IC50 Log Ki	4 7	IC50 IC50	mg kg-1 molar ratio	295 178		
Potency log IC50	11	IC50	ug	117		
		IC50 IC50	% uM well-1	113 52		
>5000 types		IC50 IC50	p.p.m. ppm	51 36		
		IC50	uM-1	25		
		IC50 IC50	nM kg-1 milliequivalent	25 22		
		IC50	kJ m−2	20		

Implemented using the Quantities, Dimension, Units, Types Ontology (http://www.qudt.org/)

~ 100 units

### **Data Licensing Solution**



#### Chose John Wilbanks as consultant

A framework built around STANDARD well-understood Creative Commons licences – and how they interoperate




#### Deal with the problems by:

- Interoperable licences
- Appropriate terms
- Declare expectations to users and data publishers
- One size won't fit all requirements


Compatibility chart		Terms that may be used for a derivative work or adaptation						
		BY	BY-NC	BY-NC-ND	BY-NC-SA	BY-ND	BY-SA	PD
	PD							
	BY							
	BY-NC							
Status of original work	BY-NC-ND							
-	BY-NC-SA							
	BY-ND							
	BY-SA							





http://explorer.openphacts.org/





### **Example applications**




ChemBioNavigator	Navigating at the interface of chemical and
Onembionavigator	biological data with sorting and plotting options
TargetDossier	Interconnecting Open PHACTS with multiple target centric services. Exploring target similarity using diverse criteria
PharmaTrek	Interactive Polypharmacology space of experimental annotations
UTOPIA	Semantic enrichment of scientific PDFs

## **Predictions**

GARFIELD	Prediction of target pharmacology based on the Similar Ensemble Approach
eTOX connector	Automatic extraction of data for building predictive toxicology models in eTOX project
















#### **Bioclipse**














Public Content



**Annotations** 



Commercial

## **RDF Guidelines**



#### Guidelines for exposing data as RDF in Open PHACTS

Open PHACTS Working Draft 23 August 2012

This version:

http://www.openphacts.org/specs/2012/WD-rdfquide-20120823/

Latest published version:

http://www.openphacts.org/specs/rdfguide/

Latest editor's draft:

http://www.bigcat.unimaas.nl/~egonw/rdfguide/

Previous version:

none

Editor:

# Step 9: who, what, when, why, how



#### Dataset Descriptions for the Open Pharmacological Space

Open PHACTS Working Draft 19 October 2012

This version:

http://www.openphacts.org/specs/2012/WD-datadesc-20121019/

Latest published version:

http://www.openphacts.org/specs/datadesc/

Latest editor's draft:

http://www.cs.man.ac.uk/~graya/ops/2012/ED-datadesc/

Previous version:

http://www.openphacts.org/specs/2012/WD-datadesc-20120816/

Editor:

# Step 9: who, what, when, why, how

```
# Description of the ChemSpider dataset
:chemSpiderDataset
# General metadata
        a void:Dataset:
        dcterms:title "ChemSpider"@en;
        dcterms:description "ChemSpider's Public Dataset"@en;
        foaf:homepage <http://rdf.chemspider.com/>;
        foaf:page <http://www.chemspider.com/>;
        dcterms:license <http://www.chemspider.com/Disclaimer.aspx>;
        void:uriSpace "http://rdf.chemspider.com/"^^xsd:string;
#Provenance
        dcterms:publisher <http://www.chemspider.com/>;
        dcterms:created "2007-03-01T00:00:00"^^xsd:dateTime:
        dcterms:modified "2012-10-16T00:00:00"^^xsd:dateTime;#Subsets
        void:subset :chemSpiderDataset chembl subset,:chemSpiderDataset drugbank subset;
#Vocabularies, topics, resources
        void:vocabulary <http://purl.org/dc/elements/1.1/>,
                <http://purl.org/dc/terms/>,
                 <a href="http://www.openarchives.org/ore/terms/">http://www.openarchives.org/ore/terms/>,</a>,
                 <http://www.polymerinformatics.com/ChemAxiom/ChemDomain.owl#>,
                 <http://xmlns.com/foaf/0.1/>;
        dcterms:subject <http://dbpedia.org/resource/Molecule>;
        void:exampleResource <http://rdf.chemspider.com/2157>;
#Dataset Access
        void:sparqlEndpoint <http://rdf.chemspider.com/sparql>;
#Update Frequency
        voag:frequencyOfChange freq:continuous;
#Other Metadata
        # Technical features
        void:feature <http://www.w3.org/ns/formats/RDF XML>;
        # Dataset statistics
        void:triples "1157624328"^^xsd:nonNegativeInteger;
```



# Community

## Open PHACTS and the

## scientific community



### Associated partners

Organisations, most will join here

Support, information

Exchange of ideas, data, technology

Opportunities to demo at community webinars

**Need MoU** 

### Development partnerships


Influence on API developments

Opportunities to demo ideas & use cases to core team

Need MoU and annexe

#### Consortium

28 current members



#### **Associate Partners**





























































# Wrap up



- Open Source and Open Data solutions
  - Used and Developed
- Specifications
  - http://www.openphacts.org/specs/
- Solutions for pharma

"Shaping the future of Open PHACTS"
 5th Community Workshop, Amsterdam 10-11 Oct

www.openphacts.org